e-learning
resources
Berlin 2008
Wednesday, 08.10.2008
Recent advances in the treatment and pathogenesis of pulmonary diseases II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Use of multifactor-dimensionality reduction model predicting bronchodilator response by inhaled short-acting beta 2 agonist
S. H. Kim, S. M. Lee, S. H. Lee, E. S. Shin, J. E. Lee, H. W. Park, S. S. Kim, S. H. Cho, K. U. Min, Y. Y. Kim (Seoul, Republic Of Korea)
Source:
Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Session:
Recent advances in the treatment and pathogenesis of pulmonary diseases II
Session type:
E-Communication Session
Number:
4641
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. H. Kim, S. M. Lee, S. H. Lee, E. S. Shin, J. E. Lee, H. W. Park, S. S. Kim, S. H. Cho, K. U. Min, Y. Y. Kim (Seoul, Republic Of Korea). Use of multifactor-dimensionality reduction model predicting bronchodilator response by inhaled short-acting beta 2 agonist. Eur Respir J 2008; 32: Suppl. 52, 4641
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
ERS short guidelines on COVID-19 management
Related content which might interest you:
Use of partition tree to Identify genetic marker combination predicting bronchodilator response by inhaled short-acting beta 2 agonist
Source: Annual Congress 2011 - Genetics of airway diseases and treatment
Year: 2011
What predicts short-acting beta agonist (SABA) monotherapy use in children?
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004
Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids
Source: Annual Congress 2007 - Respiratory issues in primary care
Year: 2007
Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007
Protective effect of inhaled glucocorticosteroid and long-acting beta2-agonist combination on COPD model
Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases
Year: 2021
Increased doses of inhaled corticosteroids versus addition of long-acting beta2 agonists for treatment of asthma
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010
The impact of tiotropium on mortality when added to inhaled corticosteroids and long-acting beta agonist therapy in COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007
The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments
Source: International Congress 2015 – New insights into exercise and muscle performance
Year: 2015
PF-00610355 – an inhaled β
2
adrenoceptor agonist with superior potency and duration of action (DoA) to salmeterol in the conscious dog model of bronchoconstriction
Source: Annual Congress 2009 - Models of chronic airways disease and therapy
Year: 2009
Effect of inhaled beta2 agonist on lung compliance in patients with COPD with poor bronchodilator response
Source: Eur Respir J 2006; 28: Suppl. 50, 428s
Year: 2006
Factors influencing the relative effect of leukotriene receptor antagonists (LTRA) and inhaled corticosteroids (ICS) as monotherapy in persistent asthma: A systematic review
Source: Annual Congress 2011 - Asthma management and response
Year: 2011
Vilanterol, a novel inhaled long-acting β
2
adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Compound X – an inhaled β
2
agonist with equivalent potency and superior duration of action (DOA)/ therapeutic index (TI) to salmeterol in the anaesthetised dog model of bronchoconstriction
Source: Annual Congress 2008 - Novel treatments for respiratory disease
Year: 2008
Short-acting beta-agonist (SABA) and airway inflammation: dynamic negative interaction
Source: Eur Respir J 2002; 20: Suppl. 38, 110s
Year: 2002
Tiotropium bromide (TIO) reduces hospitalizations in patients with COPD who had been refractory to treatment with combined inhaled corticosteroid/long acting beta agonist (ICS/LABA)
Source: Eur Respir J 2005; 26: Suppl. 49, 717s
Year: 2005
Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness
Source: Eur Respir J 2006; 27: 1144-1151
Year: 2006
Is there a problem with short-acting beta-2 agonist monotherapy in asthma?
Source: Virtual Congress 2020 – Airway diseases
Year: 2020
Using rates of inhaled long acting beta 2 agonist and corticosteroids in asthma and COPD patients
Source: Eur Respir J 2002; 20: Suppl. 38, 110s
Year: 2002
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept